New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19
Reads0
Chats0
TLDR
In this article , the authors report on nine patients (eight cases of MS and one case of NMOSD) who presented a disease relapse in close temporal association with their first AZD1222 vaccination dose against COVID-19.Abstract:
We report on nine patients (eight cases of MS and one case of NMOSD) who presented a disease relapse in close temporal association with their first AZD1222 vaccination dose against COVID-19. These patients had been stable for a median period of six years, with no evidence of disease activity and no change in their medication. After a median of 13 days (7 to 25 days) from vaccination, they developed a new relapse with increased disability and new lesions on magnetic resonance imaging. Although this association may be rare, it might be an adverse event of AZD1222. read more
Citations
More filters
Journal ArticleDOI
Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD
Alessandro Dinoto,Elia Sechi,Sergio Ferrari,Alberto Gajofatto,Riccardo Orlandi,Paolo Solla,Alessandra Maccabeo,Alessandra Maccabeo,Giorgia Teresa Maniscalco,Vincenzo Andreone,Arianna Sartori,Paolo Manganotti,Sarah Rasia,Ruggero Capra,Chiara Rosa Mancinelli,Sara Mariotto +15 more
TL;DR: In this paper, the frequency of relapses within one month of SARS-CoV-2 vaccination was 4% (1/26) in the AQP4-IgG+NMOSD group and 0% in the MOGAD group.
Journal ArticleDOI
Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD
TL;DR: In this paper , the frequency of relapses within one month of SARS-CoV-2 vaccination was 4% (1/26) in the AQP4-IgG+NMOSD group and 0% in the MOGAD group.
Journal ArticleDOI
To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection
Dominika Stastna,Ingrid Menkyová,Jiri Drahota,Tereza Hrnciarova,Eva Havrdova,M. Vachova,Michaela Andelova,P. Kleinova,I. Kovarova,Eva Krasulova,Jana Lizrova Preiningerova,I. Novakova,Klara Novotna,Martina Novotna,Petra Nytrova,Jana Pavlíčková,Barbora Srpova,Kateřina Storey,Veronika Tichá,Michaela Tyblova,Tomas Uher,Karolina Vodehnalova,Dana Horakova +22 more
TL;DR: In this article , the authors evaluated a short-term risk of relapse after COVID-19 vaccination and infection in patients with demyelinating disorders of the central nervous system and to determine disease exacerbation risk factors.
Journal ArticleDOI
CNS inflammatory demyelinating events after COVID-19 vaccines: A case series and systematic review
Virginia Rinaldi,Gianmarco Bellucci,Maria Chiara Buscarinu,Roberta Reniè,Antônio Carlos Huf Marrone,Martina Nasello,Valeria Zancan,Riccardo Nistri,Roberto Palumbo,Antonio Salerno,Marco Salvetti,Giovanni Ristori +11 more
TL;DR: In this article , the authors performed a systematic literature search of post-COVID-19 vaccines CIDEs, including ATM, ADEM, MS, and NMOSD/MOGAD, published worldwide between December 2020 and December 2021.
Journal ArticleDOI
Multiple sclerosis relapse after COVID-19 vaccination: A case report-based systematic review
Fardin Nabizadeh,Elham Ramezannezhad,Kimia Kazemzadeh,Elham Khalili,E. M. Ghaffary,Omid Mirmosayyeb +5 more
TL;DR: Wang et al. as discussed by the authors performed a systematic review of case reports and case series studies to investigate the MS relapses after COVID-19 vaccination with most details, and they systematically searched three databases, including PubMed, Scopus, and Web of Science, in February 2022.
References
More filters
Journal ArticleDOI
The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.
Ivaylo I. Ivanov,Brent S. McKenzie,Liang Zhou,Carlos E. Tadokoro,Alice Lepelley,Juan J. Lafaille,Daniel J. Cua,Dan R. Littman +7 more
TL;DR: It is shown that the orphan nuclear receptor RORgammat is the key transcription factor that orchestrates the differentiation of this effector cell lineage of proinflammatory T helper cells and its potential as a therapeutic target in inflammatory diseases is highlighted.
Journal ArticleDOI
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Merryn Voysey,Clemens Sac.,Shabir A. Madhi,Lily Yin Weckx,P M Folegatti,Parvinder K. Aley,Brian Angus,Vicky L. Baillie,Shaun Barnabas,Q E Bhorat,S Bibi,Carmen Briner,P Cicconi,Andrea M. Collins,R Colin-Jones,Clare L. Cutland,Thomas C. Darton,Keertan Dheda,Duncan Cja.,Emary Krw.,Katie J. Ewer,Lee Fairlie,Saul N. Faust,Shuo Feng,Daniela M. Ferreira,Adam Finn,Anna Goodman,Catherine M. Green,Christopher A Green,Paul T. Heath,Christopher Hill,Helen Hill,Ian Hirsch,Hodgson Shc.,Allen Izu,S Jackson,D Jenkin,Joe Ccd.,S Kerridge,Anthonet Koen,Gaurav Kwatra,Rajeka Lazarus,Alison M. Lawrie,A Lelliott,Vincenzo Libri,Patrick J. Lillie,R Mallory,Mendes Ava.,Eveline Pipolo Milan,Angela M. Minassian,Alastair McGregor,Hazel Morrison,Y Mujadidi,Amit J Nana,P J O’Reilly,S D Padayachee,A Pittella,E Plested,Katrina M Pollock,M N Ramasamy,S Rhead,Alexandre Vargas Schwarzbold,Nisha Singh,Andrew Smith,R Song,Matthew D. Snape,Eduardo Sprinz,Rebecca K. Sutherland,R Tarrant,E. Thomson,M E Török,Mark Toshner,Turner Dpj.,Johan Vekemans,Tonya Villafana,Watson Mee.,C J Williams,Alexander D. Douglas,Hill Avs.,Teresa Lambe,Sarah C. Gilbert,Andrew J. Pollard +81 more
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Journal ArticleDOI
T cell activation.
TL;DR: This year marks the 25th anniversary of the first Annual Review of Immunology article to describe features of the T cell antigen receptor (TCR), with a description of the current state of the understanding of TCR signaling and a summary of recent findings.
Journal ArticleDOI
NF-κB, inflammation, immunity and cancer: coming of age
Koji Taniguchi,Michael Karin +1 more
TL;DR: How the initial discovery of a role for NF-κB in linking inflammation and cancer led to an improved understanding of tumour-elicited inflammation and its effects on anticancer immunity is discussed.
Journal ArticleDOI
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.
Andreas Greinacher,Thomas Thiele,Theodore E. Warkentin,Karin Weisser,Paul A. Kyrle,Sabine Eichinger +5 more
TL;DR: In this article, the authors reported several cases of unusual thrombotic events and thrombo-cellocytopenia after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of spike proteins.